Literature DB >> 12193477

Vascular endothelial growth factor and Kaposi's sarcoma cells in human skin grafts.

Felipe Samaniego1, Daniel Young, Cara Grimes, Vanessa Prospero, Melpo Christofidou-Solomidou, Horace M DeLisser, Om Prakash, Aysegul A Sahin, Suizhao Wang.   

Abstract

Human cancer cells often produce tumors in animal models that incompletely reproduce the histology of the parental tumor. Kaposi's sarcoma (KS) cells, in particular, have not produced durable angiogenic lesions in animal models that resemble those of KS in humans. We investigated the contribution of transformed KS cells, vascular endothelial growth factor (VEGF), and human skin tissue on tumor development in a human skin graft/mouse model. High levels of serum VEGF (322 pg/ml) were seen in HIV-1-infected persons with KS compared with HIV-1-infected persons without KS (115 pg/ml). Human KS lesions expressed VEGF in the spindle cells. Transformed KS cells expressed the mitogenically active 121-amino acid and 165-amino acid isoforms of VEGF. Tumors induced by KS cells implanted in the SCID mice grew preferentially in human skin grafts rather than in ungrafted murine skin. Tumors induced in the presence of human skin grafts developed numerous lumens expressing alpha(v)beta(3) integrin. KS cells inoculated with neutralizing anti-VEGF antibody did not form tumors. This study supports an important role for VEGF in tumor development and shows how a human tissue can preferentially promote tumor growth.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12193477

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  12 in total

Review 1.  Molecular biology of KSHV in relation to AIDS-associated oncogenesis.

Authors:  Whitney Greene; Kurt Kuhne; Fengchun Ye; Jiguo Chen; Fuchun Zhou; Xiufen Lei; Shou-Jiang Gao
Journal:  Cancer Treat Res       Date:  2007

Review 2.  Molecular biology of Kaposi's sarcoma-associated herpesvirus and related oncogenesis.

Authors:  Qiliang Cai; Suhbash C Verma; Jie Lu; Erle S Robertson
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

3.  Recent publications by ochsner authors.

Authors: 
Journal:  Ochsner J       Date:  2003

4.  Activation of Src kinase Lyn by the Kaposi sarcoma-associated herpesvirus K1 protein: implications for lymphomagenesis.

Authors:  Om Prakash; O Rama Swamy; Xiochang Peng; Zhen-Ya Tang; Li Li; Janet E Larson; J Craig Cohen; Javed Gill; Gist Farr; Suizhao Wang; Felipe Samaniego
Journal:  Blood       Date:  2005-01-21       Impact factor: 22.113

5.  12E2: a cloned murine dermal cell with features of dermal dendrocytes and capacity to produce pathologic changes resembling early Kaposi's sarcoma.

Authors:  Masatoshi Deguchi; Diana Whitaker-Menezes; Stephen C Jones; Setsuya Aiba; Satoshi Nakagawa; Hachiro Tagami; Robert Korngold; George F Murphy
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

6.  Angiogenesis, Kaposi's Sarcoma and Kaposi's Sarcoma-Associated Herpesvirus.

Authors:  Tao Kang; Feng-Chun Ye; Shou-Jiang Gao; Lin-Ding Wang
Journal:  Virol Sin       Date:  2008-12-01       Impact factor: 4.327

Review 7.  Targeted therapy for Kaposi sarcoma.

Authors:  Ryan J Sullivan; Liron Pantanowitz; Bruce J Dezube
Journal:  BioDrugs       Date:  2009       Impact factor: 5.807

8.  RGD targeted poly(L-glutamic acid)-cystamine-(Gd-DO3A) conjugate for detecting angiogenesis biomarker alpha(v) beta3 integrin with MRT, mapping.

Authors:  Tianyi Ke; Eun-Kee Jeong; Xuli Wang; Yi Feng; Dennis L Parker; Zheng-Rong Lu
Journal:  Int J Nanomedicine       Date:  2007

9.  Insulin-like growth factor-I receptor activity is essential for Kaposi's sarcoma growth and survival.

Authors:  S-B Catrina; M Lewitt; C Massambu; A Dricu; J Grünler; M Axelson; P Biberfeld; K Brismar
Journal:  Br J Cancer       Date:  2005-04-25       Impact factor: 7.640

10.  Viral and immunological markers of HIV-associated Kaposi sarcoma recurrence.

Authors:  Owen Ngalamika; Marie Claire Mukasine; Musonda Kawimbe; Faheema Vally
Journal:  PLoS One       Date:  2021-07-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.